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Abstract 
Network meta-analysis has been gaining prominence as an evidence synthesis method 
that enables the comprehensive synthesis and simultaneous comparison of multiple 
treatments. In many network meta-analyses, some of the constituent studies may have 
markedly different characteristics from the others, and may be influential enough to 
change the overall results. The inclusion of these “outlying” studies might lead to biases, 
yielding misleading results. In this article, we propose effective methods for detecting 
outlying and influential studies in a frequentist framework. In particular, we propose 
suitable influence measures for network meta-analysis models that involve missing 
outcomes and adjust the degree of freedoms appropriately. We propose three influential 
measures by a leave-one-trial-out cross-validation scheme: (1) comparison-specific 
studentized residual, (2) relative change measure for covariance matrix of the 
comparative effectiveness parameters, (3) relative change measure for heterogeneity 
covariance matrix. We also propose (4) a model-based approach using a likelihood ratio 
statistic by a mean-shifted outlier detection model. We illustrate the effectiveness of the 
proposed methods via applications to a network meta-analysis of antihypertensive drugs. 
Using the four proposed methods, we could detect three potential influential trials 
involving an obvious outlier that was retracted because of data falsifications. We also 
demonstrate that the overall results of comparative efficacy estimates and the ranking of 
drugs were altered by omitting these three influential studies. 
 
Key words: network meta-analysis; contrast-based model; outlier detection; influence 
diagnostics; multivariate meta-analysis 
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1. Introduction 
Network meta-analysis has been gaining prominence as an evidence synthesis method 
that enables the comprehensive synthesis and simultaneous comparison of multiple 
treatments. The methodology can synthesize both direct and indirect evidence for all 
treatment comparisons of interest, and provides estimates of comparative efficacies 
among treatments, even when no direct comparison evidence exists for some of the 
included treatments 1,2. 
In network meta-analysis, there are often systematic heterogeneities among the 
synthesized studies, e.g., study designs, participant characteristics, regions, sites, 
treatment administration, interventions, outcome definitions, etc. Therefore, 
heterogeneity of the effect sizes is common, and random-effects models have been 
adopted as standard tools for evidence synthesis 1-4. However, in many practices of 
network meta-analysis, some studies might have markedly different characteristics from 
others, and may exceed the degree of statistical heterogeneity that can be adequately 
explained by the random-effects model. As in conventional outlier problems in traditional 
regression analyses 5, these “outlying studies” might lead to biases, potentially yielding 
misleading results 6. The evidence obtained from network meta-analyses has already been 
widely used for public health, clinical practices, health technology assessments, and 
policy-making, so the identification and influence diagnostics of the outlying studies are 
relevant issues to prevent serious influences for the various applications. 
To detect outliers and assess their influences in network meta-analyses, Zhang et al. 6 
recently developed Bayesian influence diagnostic methods for detecting trial-level 
outliers. Their methods are effectively applicable to Bayesian analyses of arm-based and 
contrast-based models. However, due to the developments of many useful software 
packages such as netmeta7 in R and network8 and network graphs9 in Stata, 
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frequentist methods for the contrast-based multivariate random-effects model have been 
widely adopted in recent practice. These methods do not require complicated 
computational techniques such as the Markov Chain Monte Carlo (MCMC) or its 
convergence diagnostics, and are easily tractable for non-statisticians 8,10,11; thus, they 
have already been used as alternative standard methods in network meta-analysis. To date, 
however, there are no effective methods for detecting outliers for use with the frequentist 
methods of network meta-analysis.  
For frequentist inference methods of the conventional univariate meta-analysis, 
several useful influence diagnosis methods were developed by Viechtbauer and Chueng12 
and Gumedze and Jackson13. Also, Negeri and Beyene14 generalized their methods to the 
bivariate random-effects model for meta-analyses of diagnostic test accuracy (DTA) 
studies; but the DTA meta-analyses involve only two outcome variables, and complete 
observations are usually obtained for both of the two outcome variables, sensitivity and 
specificity15. In network meta-analysis, the dimension of the multivariate model is usually 
not small (for the illustrative example of antihypertensive drugs16 in Sections 2 and 6, the 
dimension was 7), and most of the components of outcome variables for the multivariate 
model are “missing” (not defined) because most individual trials usually involve only two 
to five arms. 
In this article, we propose effective frequentist methods for identification and 
influential diagnostics of outlying studies in network meta-analyses. In particular, we 
propose suitable influence measures for the network meta-analysis models that involve 
missing outcomes and adjust the degree of freedoms appropriately. We propose three 
influential measures by a leave-one-trial-out cross-validated scheme: (1) comparison-
specific studentized residual, (2) relative change measure for covariance matrix of the 
comparative effectiveness parameters, (3) relative change measure for heterogeneity 
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covariance matrix. We also propose (4) a model-based approach using a likelihood ratio 
statistic by a mean-shifted outlier detection model. Note that the proposed methods are 
generally applicable for multivariate meta-analyses involving missing outcomes17,18. We 
illustrate the effectiveness of the proposed methods by applying them to the network 
meta-analysis of antihypertensive drugs of Sciarretta et al, 16 which involves an obvious 
outlying study in the dataset, as will be explained in Section 2. We show that the outlying 
trial was clearly detectable by all four of the proposed methods; another two trials were 
also similarly detected. We also demonstrate that the overall results of comparative 
efficacy estimates and the ranking of drugs were changed by exclusion of the three 
influential studies. 
 
2. Motivating example: A network meta-analysis of antihypertensive drugs 
The motivating example is the network meta-analysis of antihypertensive drugs of 
Sciarretta et al. 16 The authors reviewed 26 randomized controlled trials (223,313 
participants) from 1997 to 2009, which compared seven antihypertensive drugs [α-
blocker (AB), angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor 
blocker (ARB), β-blocker (BB), calcium channel blocker (CCB), conventional treatment 
(CT), and diuretic (DD)] and placebo. The efficacy outcome was the incidence of heart 
failure. Sciarretta et al. assessed the comparative odds ratios (ORs) using network meta-
analysis. We present the original dataset in Table 1 and the network plot for this network 
meta-analysis in Figure 1. Most of the trials were two-arm trials; only two were three-
arm trials (STOP-2 and ALLHAT). Note that the Jikei Heart Study was a randomised 
clinical trial that compared ARB and CT, but the paper describing the main results 19 was 
retracted from Lancet due to misconduct: some falsifications appeared in the published 
data, and the treatment effect of ARB may have been overestimated. The original network 
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meta-analysis by Sciarretta et al. 16 included this study; consequently, the overall 
comparative efficacy estimates might have been biased. Therefore, we considered that the 
Jikei Heart Study might be an influential outlier in this comparative study. However, to 
date there are no effective methods for assessing the influences of such trials to the overall 
comparative results by frequentist framework. Thus, we aimed to develop effective 
methods to provide useful insights for critical evaluations and appropriate interpretations 
of network meta-analysis in practice. 
 
3. Multivariate random-effects model for network meta-analysis  
We adopt the contrast-based, multivariate random-effects model for network meta-
analysis 8,20. We consider synthesizing 𝑁 trials and comparing 𝑝 + 1 treatments. Let 
𝑌𝑖𝑗  denote an estimator of treatment effect in contrast to a reference treatment (e.g., 
placebo) for the jth treatment in the 𝑖th trial (𝑖 = 1, 2, … , 𝑁; 𝑗 = 1,2, … , 𝑝). Commonly 
used effect measures include mean difference, standardized mean difference, risk 
difference, risk ratio, odds ratio, and hazard ratio; the ratio measures are usually 
transformed on a logarithmic scale. For appropriate modelling of within- and between-
studies correlations, we consider multivariate outcome variable 𝒀𝑖 = (𝑌𝑖1, 𝑌𝑖2, … , 𝑌𝑖𝑝)
𝑇
. 
Also, let 𝑺𝑖 (a 𝑝 × 𝑝 matrix) be the within-study covariance matrix, which is assumed 
to be known and fixed to its valid estimate. For the within-study covariance estimators, 
the Wei and Higgins 21 estimators can be adopted. Note that for trials that do not include 
a reference treatment, the data augmentation approach of White et al. 3 can be adopted; a 
quasi-small dataset is added into the reference arm, e.g., 0.001 events for 0.01 patients. 
Also, most individual clinical trials typically involve only two to five arms, so many of 
the components of 𝒀𝑖  are usually undefined. We formally regard these undefined 
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components as “missing.” The frequentist inferences can be validly implemented for the 
incomplete outcomes; there have been many theoretical and numerical evidence 20,22. 
The multivariate random-effects model for network meta-analysis can be given as 
𝒀𝑖~MVN(𝜽𝑖 , 𝑺𝑖), 𝜽𝑖~MVN(𝝁,𝚿)                  (*) 
𝑺𝑖 =
(
 
 
𝑠𝑖1
2 𝜌𝑖12𝑠𝑖1𝑠𝑖2 ⋯ 𝜌𝑖1𝑝𝑠𝑖1𝑠𝑖𝑝
𝜌𝑖12𝑠𝑖1𝑠𝑖2 𝑠𝑖2
2 … 𝜌𝑖2𝑝𝑠𝑖2𝑠𝑖𝑝
⋮ ⋮ ⋱ ⋮
𝜌𝑖1𝑝𝑠𝑖1𝑠𝑖𝑝 𝜌𝑖2𝑝𝑠𝑖2𝑠𝑖𝑝 ⋯ 𝑠𝑖𝑝
2
)
 
 
 
 𝚿 =
(
 
 
𝜏1
2 𝜅12𝜏1𝜏2 ⋯ 𝜅1𝑝𝜏1𝜏𝑝
𝜅12𝜏1𝜏2 𝜏2
2 … 𝜅2𝑝𝜏2𝜏𝑝
⋮ ⋮ ⋱ ⋮
𝜅1𝑝𝜏1𝜏𝑝 𝜅2𝑝𝜏2𝜏𝑝 ⋯ 𝜏𝑝
2
)
 
 
 
where 𝜽𝑖 = (𝜃𝑖1, 𝜃𝑖2, … , 𝜃𝑖𝑝)
𝑇
, 𝝁 = (𝜇1, … , 𝜇𝑝)
𝑇
. The grand mean vector 𝝁 expresses 
the average comparative effectiveness parameters. 𝚿 is the between-studies covariance 
matrix. The correlation structure of 𝚿 can be assumed to be unstructured, but there are 
rarely enough studies to identify the all variance-covariance parameters. Thus, most 
network meta-analyses adopt the equal variance assumption 𝜏1
2 = 𝜏2
2 = ⋯ = 𝜏𝑝
2 8; then, 
all pairwise correlation coefficients 𝜅𝑖𝑗s should be equal to 0.50 due to the consistency 
assumption 23,24. We denote the inverse of the marginal covariance matrix of 𝒀𝑖  as 
𝑾𝑖 = (𝚿 + 𝑺𝑖)
−1. 
For estimation of the model parameters, the log-likelihood function of the multivariate 
meta-analysis model (*) is given as 
ℓ(𝝁,𝚿) = −
1
2
∑{log{det (𝚿 + 𝑺𝑖)} + (𝒚𝑖 − 𝝁)
𝑇𝑾𝑖(𝒚𝑖 − 𝝁) + 𝑝𝑖 log 2𝜋}
𝑁
𝑖=1
 
where 𝑝𝑖 is the number of observed outcomes in 𝒀𝑖. Also, 𝒀𝑖 and 𝑺𝑖 involve missing 
components, as mentioned above. In the log-likelihood function, these are shrunk to the 
sub-vector and sub-matrix for the observed components. In addition, another standard 
6 
 
 
efficient estimation method is the restricted maximum likelihood (REML) estimation. 
The log-restricted likelihood function is written as 
ℓ𝑅𝐿(𝝁,𝚿) = 𝑐𝑜𝑛𝑠𝑡. +ℓ(𝝁, 𝜼) −
1
2
log {det (∑𝑾𝑖
𝑁
𝑖=1
)} 
The REML estimators of {?̂?, ?̂?} are obtained by maximizing ℓ𝑅𝐿(𝝁,𝚿). The covariance 
matrix estimator of ?̂?  is given as 𝑉[?̂?] = (∑ ?̂?𝑖
𝑁
𝑖=1 )
−1
, where ?̂?𝑖 = (?̂? + 𝑺𝑖)
−1
. 
Because it is well known that the REML estimator has favorable properties 25,26, the 
REML method is generally adopted in practice. 
 
4. Leave-one-trial-out cross-validated influential measures 
4.1 Comparison-specific studentized residual 
To detect outlying trials and their influence diagnostics, we first discuss leave-one-trial-
out cross-validated (LOTOCV)-type influential measures, which are generalized versions 
of similar measures for conventional univariate meta-analysis proposed by Viechtbauer 
and Cheung 12. 
Straightforward approaches for assessing influence include residual-based methods, 
which have been extensively discussed in regression diagnosis 5. For the multivariate 
meta-analysis model (*), we can define the studentized residuals by a straightforward 
generalization of the univariate version12 as 
𝑹𝑖 = 𝑉[𝒀𝒊 − ?̂?]
−
1
2(𝒀𝒊 − ?̂?) 
where 𝑉[𝒀𝒊 − ?̂?] = ?̂?𝑖
−1 − (∑ ?̂?𝑖
𝑁
𝑖=1 )
−1
 (𝑖 = 1,2, … ,𝑁). This multivariate studentized 
residuals were also proposed by Negeri and Beyene 14 for the bivariate random-effects 
model of DTA meta-analysis. However, as noted above, there are not missing outcomes 
in DTA meta-analysis, whereas network meta-analysis models usually involve many 
missing outcomes. Thus, the dimensions of the multivariate studentized residuals usually 
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differ among the 𝑁 trials. Also, their individual components might not be intuitively 
interpreted as influences to the effect-size estimation, as the multivariate measure is 
studentized as a 𝑝𝑖 dimensional vector; the individual components are interpreted solely 
as their components. Therefore, we propose to use a comparison-specific studentized 
residual for the influence diagnosis in network meta-analysis: 
𝜙𝑖𝑗 =
𝑌𝑖𝑗 − ?̂?𝑗
√𝑉[𝑌𝑖𝑗 − ?̂?𝑗]
 
where ?̂?𝑗  is the jth component of ?̂?  ( 𝑖 = 1,2, … ,𝑁; 𝑗 = 1,2, … , 𝑝 ). 𝑉[𝑌𝑖𝑗 − ?̂?𝑗] 
accords to the (j, j)-component of 𝑉[𝒀𝒊 − ?̂?] . The comparison-specific studentized 
residual is interpreted as a standardized residual of the effect-size estimator, and is 
comparable among all pairwise treatment comparisons and all N trials, which usually 
involve different combinations of treatments. Note that if the ith trial does not involve the 
reference arm, 𝑌𝑖𝑗 is defined as a contrast estimate between the jth treatment and data-
augmented reference treatment. For this case, the standard error (SE) estimate of the 
residual 𝑌𝑖𝑗 − ?̂?𝑗 can be unstable. Therefore, we recommend changing the reference 
treatment to one of the involved treatment arms for the ith trial. Then, 𝑌𝑖𝑗 corresponds 
to a head-to-head comparison estimator, and the comparison-specific studentized residual 
𝜙𝑖𝑗 is intuitively interpreted as a residual measure of the direct comparison estimator. 
In addition, as is well known in regression diagnosis5, the naïve studentized residual 
𝜙𝑖𝑗 assesses the divergence of the ith trial from the overall mean estimate ?̂?𝑗, which is 
estimated using the information of the ith trial itself. Thus, the naïve residual 𝜙𝑖𝑗 might 
not be a suitable measure of influence assessments because it can involve “optimism”. 
Thus, LOTOCV-type measures have been proposed to circumvent the optimism. Let 
?̂?(−𝑖), ?̂?(−𝑖)  be the REML estimates obtained from the multivariate random-effects 
model (*) by an 𝑁 − 1 trials dataset that excludes the ith trial (𝑖 = 1,2, … ,𝑁); we also 
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denote ?̂?𝑘
(−𝑖)
= (?̂?(−𝑖) + 𝑺𝑘)
−1
 (𝑘 = 1,2, … ,𝑁 ). Then, the LOTOCV comparison-
specific studentized residual is defined as 
𝜓𝑖𝑗 =
𝑌𝑖𝑗 − ?̂?𝑗
(−𝑖)
√𝑉[𝑌𝑖𝑗 − ?̂?𝑗
(−𝑖)
]
 
where 𝑉[𝑌𝑖𝑗 − ?̂?𝑗
(−𝑖)
] accords to the (j, j) component of 𝑉[𝒀𝒊 − ?̂?
(−𝑖)] = (?̂?𝑖
(−𝑖))
−1
+
(∑ ?̂?𝑘
(−𝑖)
𝑘≠𝑖 )
−1
 ( 𝑖 = 1,2, … , 𝑁; 𝑗 = 1,2, … , 𝑝 ). Note that ?̂?(−𝑖)  and ?̂?(−𝑖)  are 
estimated by the 𝑁 − 1 trials dataset that excludes the ith trial; thus, 𝜓𝑖𝑗 is interpreted 
a predicted studentized residual of jth component of 𝑖 th trial from the estimated 
multivariate random-effects model (*) by the other 𝑁 − 1 trials. 
When the assumed model (*) is correct, the studentized residual 𝜓𝑖𝑗 follows N(0,1). 
Thus, a naïve criterion to assess for outliers is comparing 1.96 with the absolute value of 
𝜓𝑖𝑗. If the criterion is fulfilled, the corresponding comparison can be considered as a 
potential outlier. Also, an alternative more precise evaluation of its sampling variation can 
be conducted using parametric bootstrap. The parametric bootstrap algorithm is given as 
follows. 
 
Algorithm 1 (Parametric bootstrap for estimating the sampling distribution of 𝜓𝑖𝑗).  
1. For the multivariate random effects model (*), compute the REML estimates of {𝝁,𝚿}. 
2. Resample 𝒀1
(𝑏)
, 𝒀2
(𝑏)
, … , 𝒀𝑁
(𝑏)
  from the estimated distribution of (*) with the 
parameters substituted with {?̂?, ?̂?} via parametric bootstrap, B times (b = 1,2,…,B). 
3. Compute the LOTOCV studentized residuals 𝜓𝑖𝑗
(𝑏)
 (𝑖 = 1,2, … ,𝑁; 𝑗 = 1,2, … , 𝑝) for 
the bth bootstrap sample 𝒀1
(𝑏)
, 𝒀2
(𝑏)
, … , 𝒀𝑁
(𝑏)
; replicate it for all B bootstrap samples. 
4. We can obtain the bootstrap estimate of the sampling distribution of 𝜓𝑖𝑗  by the 
empirical distribution of 𝜓𝑖𝑗
(1)
, 𝜓𝑖𝑗
(2)
, … , 𝜓𝑖𝑗
(𝐵)
. 
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Typically, the 2.5th and 97.5th percentiles of the bootstrap samples 𝜓𝑖𝑗
(1)
, 𝜓𝑖𝑗
(2)
, … , 𝜓𝑖𝑗
(𝐵)
 
can be used for the critical values. 
 
4.2 Relative change for the covariance matrix of ?̂? 
Viechtbauer and Cheung12 and Negeri and Beyene14 proposed another influence measure 
that assesses the change in the covariance matrix of the grand mean parameter estimates 
by the LOTOCV framework. They proposed using the ratio of generalized variances of 
the estimators of μ for the leave-one-trial-out dataset and the all-trial dataset. It can be 
applied similarly to the multivariate random-effects model (*) as an influential measure 
of network meta-analysis, 
COVRATIO𝑖 =
det(𝑉[?̂?(−𝑖)])
det(𝑉[?̂?])
=
det ((∑ ?̂?𝑘
(−𝑖)
𝑘≠𝑖 )
−1
)
det ((∑ ?̂?𝑘
𝑁
𝑘=1 )
−1
)
 
COVRATIOi has values in (0,∞). This measure assesses the relative change of the 
covariance matrix of ?̂? when the ith trial is excluded. If COVRATIOi is nearly 1, the 
covariance matrix is not so changed and the exclusion of ith trial is not so influential. 
When COVRATIOi is larger than 1, the exclusion of the ith trial gains the variation of the 
grand mean estimator ?̂?. Then, the ith trial is influential as a means of gaining precision, 
but is not usually an outlying trial that deviates from the overall population and may 
increase the between-studies heterogeneity. On the contrary, when COVRATIOi is smaller 
than 1, the inclusion of the ith trial gains the variation of the grand mean estimator ?̂?, 
although the sample size is increased. It means the ith trial is influential as means of 
decreasing precision, and it might also gain the between-studies heterogeneity. Then, the 
ith trial might be an outlying trial that is deviated from the overall population. Thus, the 
trials with the smallest COVRATIOi may be outlying and influential trials. For the 
criterion of assessing outliers, we can also use the bootstrap sampling distribution as 
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discussed in Section 4.1. Substituting 𝜓𝑖𝑗 for COVRATIOi in Algorithm 1, we can 
obtain the bootstrap estimate of the sampling distribution for COVRATIOi. Typically, the 
lower 5th percentile of the bootstrap samples can be used for the critical value. 
 
4.3 Relative change for the estimate of heterogeneity covariance matrix ?̂? 
Negeri and Beyene14 proposed an alternative influence measure that directly assesses the 
change in the estimate of heterogeneity covariance matrix ?̂?  using the LOTOCV 
framework. The proposed measure was the ratio of generalized variances of the estimates 
of 𝚿 for the leave-one-trial-out dataset and the all trial dataset. It can also be similarly 
applied to the multivariate random-effects model (*) of network meta-analysis, 
PSIRATIO𝑖 =
det(?̂?(−𝑖))
det(?̂?)
 
The PSIRATIOi also has values in (0,∞). This measure assesses the relative change of 
the estimate of heterogeneity covariance matrix ?̂? when the ith trial is excluded. If it is 
nearly 1, the estimate of 𝚿 is not so altered and the exclusion of ith trial is not so 
influential. When PSIRATIOi is larger than 1, the exclusion of the ith trial increases 
between-studies heterogeneity. Then, the ith trial is usually not an outlying trial that 
deviates from the overall population. Conversely, when PSIRATIOi is smaller than 1, the 
inclusion of the ith trial increases between-studies heterogeneity. Then, the ith trial might 
be an outlying trial that deviates from the overall population. Therefore, the trials with 
the smallest PSIRATIO may be outlying and influential trials. For the criterion of 
assessing outliers, the bootstrap sampling distribution can be also used. Substituting 𝜓𝑖𝑗 
for PSIRATIOi in Algorithm 1, we can obtain the bootstrap estimate of the sampling 
distribution for PSIRATIO. Typically, the lower 5th percentile of the bootstrap samples 
can be used for the critical value. 
11 
 
 
5. Model-based evaluation using a mean-shifted outlier model 
Gumedze and Jackson13 proposed a model-based approach to identifying outlying trials 
in conventional univariate meta-analysis using a random-effects variance shift model. 
Negeri and Beyene14 also proposed another mean-shift model for the bivariate model for 
DTA meta-analysis. Both papers proposed assessing the significances of the alternative 
models using the likelihood ratio statistics. Here, we propose another degree of freedom–
adjusted mean-shifted model to assess outliers for network meta-analysis. 
For a network meta-analysis using the multivariate random-effects model (*), we 
consider the influence diagnostics of the ith trial. We assume that the ith trial involves 
𝑞𝑖 + 1 arms, and that degree of freedom is 𝑞𝑖 . When the reference treatment (e.g., 
placebo) is not involved in the ith trial, the length of 𝒀𝑖  is 𝑞𝑖 + 1 , but the data-
augmented arm does not involve substantial statistical information. Thus, we suppose 
letting the reference treatment change to one of the involved arms of the ith trial by sorting 
the treatment indicators for the influence diagnostics; then, 𝑝𝑖 = 𝑞𝑖. Under the setting, 
we propose a mean-shifted outlier model that involves a location-shift parameter 𝜼 =
(𝜂𝟏, 𝜂2, … , 𝜂𝑝)
𝑇
 for assessing the influence of the ith trial. 𝜂𝑗 is a real-valued parameter 
if the jth component of 𝒀𝑖 is observed, and is strictly 0 otherwise; the length of possibly 
non-zero components for 𝜼 corresponds to 𝑝𝑖. After then, we assume a mean-shifted 
model for the random-effect of ith trial 𝜽𝑖, 
𝜽𝑖~MVN(𝝁 + 𝜼,𝚿) 
Besides, we assume the ordinary random-effects model (*) for the other 𝑁 − 1 trials. 
This model assumes that the grand mean parameters of the ith trial may diverge from 
those of the other trials. If the mean-shifted model with non-zero 𝜼 is more plausible 
than the ordinary multivariate meta-analysis model (*), the ith trial can be regarded as a 
potential outlying trial, and can be assessed by a likelihood ratio statistic. The testing 
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problem is formulated as 
H0: 𝜼 = 𝟎 vs. H1: 𝜼 ≠ 𝟎 
where the alternative hypothesis means at least one component of 𝜼 is not equal to 0. 
Under the alternative hypothesis H1, the log-likelihood function is written as 
ℓ[𝑖](𝝁, 𝜼,𝚿) = −
1
2
∑{log{det (𝚿 + 𝑺𝑘)} + (𝒚𝑘 − 𝝁)
𝑇𝑾𝑘(𝒚𝑘 − 𝝁) + 𝑝𝑘 log 2𝜋}
𝑘≠𝑖
−
1
2
{log{det (𝚿 + 𝑺𝑘)} + (𝒚𝑖 − 𝝁 − 𝜼)
𝑇𝑾𝑖(𝒚𝑖 − 𝝁 − 𝜼) + 𝑝𝑖 log 2𝜋} 
Then, the likelihood ratio statistic is given as 
𝑇[𝑖] = −2{ℓ(?̃?, ?̃?) − ℓ[𝑖](?̃?[𝑖], ?̃?[𝑖], ?̃?[𝑖])}, 
where {?̃?, ?̃?}  is the maximum likelihood (ML) estimate of the null model (*) and 
{?̃?[𝑖], ?̃?[𝑖], ?̃?[𝑖]}  is the ML estimate of the mean-shifted model for the ith trial. The 
likelihood ratio statistic 𝑇[𝑖] has a χ
2-distribution with 𝑝𝑖 degrees of freedom under the 
null hypothesis, asymptotically. Thus, an adequate critical value is 𝜒𝑝𝑖,0.95
2  that is the 
95th percentile of the χ2-distribution with 𝑝𝑖  degrees of freedom for a test with 
significance level of 5%. However, as discussed in the previous sections, the conventional 
χ2 approximation might be inappropriate. An alternative precise approach is the 
parametric bootstrap.  
 
Algorithm 2 (Parametric bootstrap for estimating the sampling distribution of 𝑇[𝑖]).  
1. Compute the ML estimates {?̃?, ?̃?} and {?̃?[𝑖], ?̃?[𝑖], ?̃?[𝑖]}. 
2. Resample 𝒀1
(𝑏)
, 𝒀2
(𝑏)
, … , 𝒀𝑁
(𝑏)
 from the estimated null model of (*), for which the 
parameters are substituted with {?̃?, ?̃?} via parametric bootstrap B times (b = 1,2,…,B). 
3. Compute the ML estimates {?̃?(𝑏), ?̃?(𝑏)} and {?̃?[𝑖]
(𝑏), ?̃?[𝑖]
(𝑏), ?̃?[𝑖]
(𝑏)
} for the bth bootstrap 
sample 𝒀1
(𝑏)
, 𝒀2
(𝑏)
, … , 𝒀𝑁
(𝑏)
 and compute the likelihood ratio statistic  
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𝑇[𝑖]
(𝑏)
= −2 {ℓ(?̃?(𝑏), ?̃?(𝑏)) − ℓ[𝑖] (?̃?[𝑖]
(𝑏), ?̃?[𝑖]
(𝑏), ?̃?[𝑖]
(𝑏)
)} 
This should be replicated for all B bootstrap samples. 
4. We can obtain the bootstrap estimate of the sampling distribution of 𝑇[𝑖]  by the 
empirical distribution of 𝑇[𝑖]
(1)
, 𝑇[𝑖]
(2), … , 𝑇[𝑖]
(𝐵)
. 
 
Typically, the 95th percentile of the bootstrap samples 𝑇[𝑖]
(1)
, 𝑇[𝑖]
(2), … , 𝑇[𝑖]
(𝐵)
 can be used for 
critical values for a test with a significance level of 5%. 
 
6. Applications to a comparative study of antihypertensive drugs 
We analyzed the network meta-analysis of antihypertensive drugs described in Section 2 
by the proposed methods. We used the multivariate random-effects model (*) with the 
equal heterogeneity variances assumption (𝜏1
2 = 𝜏2
2 = ⋯ = 𝜏𝑝
2). At first, the comparative 
OR estimates from all 26 trials are presented in Figure 2(a). The reference was set to 
placebo, the heterogeneity standard deviation (SD) estimate was 0.099, and substantial 
heterogeneity was observed. The ranking of treatments and comparative OR estimates 
were almost the same as those of the original Bayesian analysis using an arm-based model 
by Sciarretta et al. 16  
In Table 2, we present the results of LOTOCV comparison-specific studentized 
residuals. We show 15 comparisons with the largest absolute studentized residuals. For 
the bootstrap estimate of sampling distribution of 𝜓𝑖𝑗s, we conducted 2400 resamplings. 
There were 28 comparisons of 26 trials. The studentized residuals of most of the 28 
comparisons were distributed within both of the 95% standard normal probability interval 
(−1.96, 1.96) and the parametric bootstrap intervals. However, three comparisons 
exceeded both of these criteria (TRANSCEND: ARB vs. placebo, Jikei Heart Study: ARB 
vs. CT, and HYVET: DD vs. placebo). As expected, the Jikei Heart Study had the 
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secondary largest studentized residual (2.241) and exceeded the 97.5th percentile of the 
bootstrap distribution. 
We present the results of LOTOCV analyses of COVRATIOi and PSIRATIOi in Table 
3. We also conducted 2400 resamplings to estimate their bootstrap distributions. The 15 
studies with the smallest COVRATIOi and PSIRATIOi are presented. The ranking of the 
sizes of COVRATIOi and PSIRATIOi for the top five trials were consistent for the two 
influential statistics (TRANSCEND, HYVET, Jikei Heart Study, RENRAAL and 
ANBP2). Especially for TRANSCEND, HYVET and Jikei Heart Study, the COVRATIOi 
values exceeded the bootstrap lower 5th percentile, and were also detected as potential 
outliers by this criterion. Besides, PSIRATIOi of HYVET, and Jikei Heart Study exceeded 
the bootstrap lower 5th percentile, but TRANSCEND did not, although the raw value of 
PSIRATIOi of TRANSCEND was the smallest among the 26 trials (0.001) and the 5th 
percentile was close to it (0.000). 
In Table 4, we present the results of the model-based outlier evaluation. The 15 studies 
with the smallest bootstrap p-values are shown. The number of resamplings was 2400. 
The likelihood ratio statistic, degree of freedom, bootstrap 95th percentile, and p-value 
are shown. In these results, the three trials (TRANSCEND, Jikei Heart Study, and 
HYVET) were also significantly detected by the likelihood ratio tests. The bootstrap 95th 
percentiles did not necessarily accord to the quantile of the χ2-distribution, but the testing 
results were consistent for the 26 trials.  
As noted in Section 2, the result of the Jikei Heart Study involved falsifications, and 
the effect of ARB could be overly estimated (ARB vs. CT; OR: 0.522, 95%CI [confidence 
interval]: 0.281, 0.939). Also, the TRANSCEND compared ARB vs. placebo, and the 
result of this study indicated no preventive effect of ARB (OR: 1.047, 95%CI: 0.811, 
1.352). Besides, the overall OR estimate of ARB compared with placebo was 0.758 
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(95%CI: 0.642, 0.896). Thus, TRANSCEND would be detected as a potential outlying 
study. A possible reason that no preventive effect of ARB indicated is non-study blood-
pressure-lowering agents were used more frequently in the placebo group than in the ARB 
group 27. The effect of ARB in the trial would be counteracted owing the discrepancy of 
the concomitant agents between the two groups. Further, HYVET compared DD and 
placebo, and the OR estimate was 0.375 (95%CI: 0.217, 0.626). The overall OR estimate 
of this pair was 0.600 (95% CI: 0.487, 0.739). Thus, the efficacy of DD was largely 
estimated in HYVET relative to the other trials. A possible reason of this result is that 
HYVET was terminated at the interim analysis and the OR might be largely estimated at 
the time of termination. In addition, the loss to follow-up rate was considerably large in 
this trial; it might be because the participants were 80 years of age or older. Missing data 
have seriously compromised inferences in clinical trials 28. Note that the number of 
evaluated comparisons was reasonably large, and the multiplicity issue should be 
considered, but the frequencies of the detected trials would exceed the range of random 
errors. 
As a whole, TRANSCEND, Jikei Heart Study, and HYVET were consistently 
detected as potentially outlying and influential trials by all four proposed methods. For a 
sensitivity analysis, we conducted a synthesized analysis using 23 trials that excluded the 
three outlying trials; Figure 2(b) shows the results. After excluding the three trials, the 
heterogeneity SD estimate became markedly smaller (0.009). Thus, the SE estimates of 
the ORs became smaller as a whole, even though three trials (total participants: 12,852) 
were excluded. Due to the increase in precision, the comparative OR of CCB vs. placebo 
was changed to 0.840 (95%CI: 0.735, 0.961), and that of AB vs. placebo was changed to 
1.234 (95%CI: 1.012, 1.506); significant differences were observed. Also, because Jikei 
Heart Study was excluded, the difference of ARB and CT got smaller, and the rankings 
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of ARB and CT was reversed; although the difference was quite small. In addition, the 
OR estimate for ARB vs. placebo became larger as TRANSCEND was excluded. This 
would also influence the comparative OR estimates of the other treatments, and the 
differences vs. placebo grew larger overall. Also, because HYVET was excluded, the 
difference between DD vs. placebo grew a bit larger; however, this effect was canceled 
by the fact that TRANSCEND was excluded. These results provide different insights into 
the comparative efficacy of the seven treatments. Concerning the inconsistency on the 
network, using the node-splitting method by Dias et al.29, ARB vs. CT and DD vs. placebo 
were detected significant inconsistent edges for all 26 trials dataset (p = 0.027, 0.046), 
but they were not significantly detected after excluding the 3 trials (p = 0.313, 0.281). 
The overall treatment rankings and comparative efficacy results would be influenced by 
the potentially outlying studies, and such sensitivity analyses would provide relevant 
information for the overall interpretations of network meta-analysis. 
 
7. Discussion 
The evidence obtained from network meta-analyses has been widely applied in public 
health, clinical practices, health technology assessment, and policy making. If misleading 
evidence has been produced as a result of including inappropriate, outlying studies, the 
impact might be enormous. In this article, we proposed effective methods for detecting 
outlying and influential studies in network meta-analysis. Through an illustrative example 
of an antihypertensive drug study16, we clearly showed that the proposed methods can 
effectively detect outlying studies (especially, Jikei Heart Study), which may induce 
misleading evidence. In general practice of network meta-analysis, influence diagnosis 
tools would be effective tools for preventing misleading results and providing precise 
evidence. 
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In addition, in this article, we proposed four frequentist methods that are interpreted 
as generalized versions of existing outlier evaluating methods of conventional univariate 
meta-analysis 12,13,30. The Bayesian outlying detection methods proposed by Zhang et al. 
6 are effective tools for Bayesian approaches to network meta-analysis, but cannot be 
straightforwardly applied to frequentist analyses. The developments and disseminations 
of the frequentist tools 7-9 for network meta-analysis have been increasingly proceeding. 
They do not require complicated computation (e.g., MCMC and its convergence 
diagnosis), and should be familiar to non-statisticians. The development of frequentist 
methods for outlying detection would help practitioners to obtain precise knowledge from 
network meta-analysis. 
Also, as is noted in Sections 3 and 4, the proposed methods can be applied to general 
multivariate meta-analysis methods involving partially missing outcomes 17,18. Although 
we proposed adopting the comparison-specific studentized residuals, there might be some 
situations in which the multivariate studentized residuals are more useful. This is an issue 
that should be addressed in future studies. In addition, we proposed to use a likelihood 
ratio test for the model-based approach. Recently, Noma et al. 20 discussed the possible 
inadequacy of the conventional likelihood ratio test under certain situations of network 
meta-analysis, namely, the χ2 approximation might be violated especially under small N. 
However, they also showed that the parametric bootstrap adjustment can improve the 
validity of the inference20. Due to recent improvements in computational power, the 
computational costs of bootstrapping are not prohibitive; consequently, the use of 
bootstrap approaches is recommended. 
In conclusion, this study proposes effective tools for assessing the outlying and 
influential studies in network meta-analyses. As shown in real data applications, there 
might be influential studies that can provide misleading evidence in practice. The 
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proposed methods might provide meaningful insights to avoid possible invalid evidence. 
In addition, for future network meta-analyses, these methods might be used as standard 
methods to provide precise knowledge, at least in sensitivity analyses. 
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from Sciarretta et al. 16 
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Table 1. Summary of network meta-analysis of antihypertensive drugs 
ID Study Year Drug 1 d/n‡ Drug 2 d/n‡ Drug 3 d/n‡ 
1 Syst-Eur 1997 CCB 37/2398 Placebo 49/2297 — — 
2 Syst-China 1998 CCB 4/1253 Placebo 8/1141 — — 
3 UKPDS 1998 ACEI 12/400 BB 9/358 — — 
4 ABCD 1998 ACEI 5/235 CCB 6/235 — — 
5 VHAS 1997 CCB 2/707 DD 0/707 — — 
6 CAPPP 1999 ACEI 75/5492 CT 66/5493 — — 
7 NICS-EH 1999 CCB 0/204 DD 3/210 — — 
8 STOP-2 1999 CCB 186/2196 CT 177/2213 ACEI 149/2205 
9 INSIGHT 2000 CCB 26/3157 DD 12/3164 — — 
10 NORDIL 2000 CCB 63/5410 CT 53/5471 — — 
11 ALLHAT 2000 AB 491/9067 DD 420/15268 — — 
12 HOPE 2000 ACEI 417/4645 Placebo 535/4652 — — 
13 RENRAAL 2001 ARB 89/751 Placebo 127/762 — — 
14 LIFE 2002 ARB 153/4605 BB 161/4588 — — 
15 CONVINCE 2003 CCB 126/8179 CT 100/8297 — — 
16 ALLHAT 2002 CCB 706/9048 DD 870/15255 ACEI 612/9054 
17 VALUE 2004 ARB 354/7649 CCB 400/7596 — — 
18 ANBP2 2003 ACEI 69/3044 DD 78/3039 — — 
19 SHELL 2003 CCB 23/942 DD 19/940 — — 
20 FEVER 2005 CCB 18/4841 Placebo 27/4870 — — 
21 ASCOT-BPLA 2005 CCB 134/9639 BB 159/9618 — — 
22 E-COST 2005 ARB 35/1053 CT 41/995 — — 
23 Jikei Heart Study 2007 ARB 19/1541 CT 36/1540 — — 
24 HYVET 2008 DD 22/1933 Placebo 57/1912 — — 
25 ONTARGET 2008 ACEI 514/8576 ARB 537/8542 — — 
26 TRANSCEND 2008 ARB 134/2954 Placebo 129/2972 — — 
         
† AB: α-blocker; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; BB: β-blocker; 
CCB: calcium channel blocker; CT: conventional treatment; DD: diuretic 
‡ d: Number of incidences of heart failure; n: no. of participants. 
  
  
 
 
 Table 2. Results of outlier evaluations using the studentized deleted residual 𝜓𝑖𝑗: 15 comparisons 
with the largest absolute studentized deleted residuals 
ID Study Comparison 𝜓𝑖𝑗 
Bootstrap lower 
2.5th percentile 
Bootstrap upper 
2.5th percentile 
26 TRANSCEND ARB vs. Placebo −2.531  −2.101  2.138  
23 Jikei Heart Study ARB vs. CT 2.241  −2.016  1.998  
24 HYVET DD vs. Placebo 2.001  −2.074  1.841  
18 ANBP2 ACEI vs. DD 1.746  −2.100  1.992  
7 NICS-EH CCB vs. DD 1.499  −1.911  2.032  
21 ASCOT-BPLA CCB vs. BB 1.312  −2.116  2.199  
9 INSIGHT CCB vs. DD −1.243  −1.954  1.937  
6 CAPPP ACEI vs. CT −1.193  −1.959  2.060  
15 CONVINCE CCB vs. CT −1.119  −2.000  2.153  
2 Syst-China CCB vs. Placebo 1.013  −1.890  2.017  
14 LIFE ARB vs. BB −0.877  −2.088  2.146  
3 UKPDS ACEI vs. BB −0.877  −1.896  1.929  
22 E-COST ARB vs. CT 0.855  −2.047  1.936  
13 RENRAAL ARB vs. Placebo 0.825  −1.977  2.010  
5 VHAS CCB vs. DD −0.820  −1.915  1.948  
      
† AB: α-blocker; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; BB: β-
blocker; CCB: calcium channel blocker; CT: conventional treatment; DD: diuretic 
  
  
 
 
Table 3. Results of outlier evaluations using COVRATIOi and PSIRATIOi: 15 studies with the smallest influential statistics 
Evaluation by COVRATIOi  Evaluation by PSIRATIOi 
ID Study COVRATIOi 
Bootstrap lower 
5th percentile 
 ID Study PSIRATIOi 
Bootstrap lower 
5th percentile 
26 TRANSCEND 0.067  0.133   26 TRANSCEND 0.001  0.000  
24 HYVET 0.079  0.343   24 HYVET 0.002  0.031  
23 Jikei Heart Study 0.222  0.515   23 Jikei Heart Study 0.029  0.133  
13 RENRAAL 0.650  0.239   13 RENRAAL 0.241  0.002  
18 ANBP2 0.683  0.212   18 ANBP2 0.300  0.003  
2 Syst-China 0.717  0.778   21 ASCOT-BPLA 0.334  0.000  
20 FEVER 0.852  0.494   2 Syst-China 0.484  0.468  
1 Syst-Eur 0.991  0.376   20 FEVER 0.615  0.121  
5 VHAS 1.005  0.918   1 Syst-Eur 0.733  0.035  
7 NICS-EH 1.036  0.903   14 LIFE 0.826  0.000  
9 INSIGHT 1.107  0.564   5 VHAS 1.004  0.777  
4 ABCD 1.164  0.808   7 NICS-EH 1.066  0.767  
3 UKPDS 1.195  0.735   9 INSIGHT 1.092  0.167  
21 ASCOT-BPLA 1.242  0.232   15 CONVINCE 1.219  0.004  
22 E-COST 1.353  0.502   3 UKPDS 1.238  0.387  
         
 
 
  
  
 
 
Table 4. Results of outlier evaluations by the likelihood ratio statistic: 15 
studies with the smallest bootstrap p-values 
ID Study LR statistic df‡ 
Bootstrap 
95th percentile 
Bootstrap 
p-value 
26 TRANSCEND 6.801  1 3.930  0.012  
23 Jikei Heart Study 5.282  1 3.916  0.023  
24 HYVET 4.326  1 3.776  0.036  
18 ANBP2 3.503  1 4.040  0.068  
21 ASCOT-BPLA 2.467  1 3.904  0.118  
7 NICS-EH 2.247  1 3.844  0.129  
15 CONVINCE 1.768  1 3.845  0.193  
6 CAPPP 1.706  1 3.798  0.202  
9 INSIGHT 1.619  1 3.864  0.213  
14 LIFE 1.524  1 3.785  0.215  
13 RENRAAL 1.279  1 3.847  0.263  
2 Syst-China 1.149  1 3.922  0.288  
22 E-COST 0.867  1 3.965  0.351  
1 Syst-Eur 0.845  1 3.801  0.357  
3 UKPDS 0.805  1 3.562  0.363  
      
‡ df: degree of freedom. 
  
  
 
 
 
Figure 1. Network plot for the network meta-analysis of 26 clinical trials (AB: α-blocker; ACEI: 
angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; BB: β-blocker; 
CCB: calcium channel blocker; CT: conventional treatment; DD: diuretic). 
  
  
 
 
 
 
 
 
 
Figure 2. Confidence interval plots for the comparative odds ratio (OR) estimates: (a) by all 26 
trials; (b) sensitivity analysis excluding TRANSCEND, Jikei Heart Study, and HYVET (AB: α-
blocker; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; 
BB: β-blocker; CCB: calcium channel blocker; CT: conventional treatment; DD: diuretic). 
 
(a) Network meta-analysis by all 26 trials
(b) Sensitivity analysis excluding TRANSCEND, Jikei Heart Study and HYVET
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